AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22

The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021

AstraZeneca Pharma India receives permission for paediatric drug

It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses

AstraZeneca Pharma India PAT at Rs 10.24 crores

Board declares interim dividend of Rs 2 per equity share

Astrazeneca Pharma India Q4FY21 net profit up at Rs 27.27 Cr

The company has reported total income of Rs.826.40 crores for FY 2020-21

AstraZeneca Pharma India receives approval for supplying Osimertinib in India

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.

AstraZeneca receives CDSCO approval to launch eculizumab in India

Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome

Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)

He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience

AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025

AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr

Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth

AstraZeneca Pharma appoints Venkat Natarajan as Lead - Market Access

Currently, Venkat is Lead – Market Access, India at Pfizer